Article Text

PDF

FRI0145 Body mass density in patients with systemic lupus erythematosus
  1. DM Obradovic,
  2. RM Stojanovic,
  3. G Susic
  1. Clinical DEpartment VI, Institute of Rheumatology, Belgrade, Yugoslavia

Abstract

Background Physiological processes, as ageing and menopause, natural influence (diet, physical activity) and many other factors are important in development of osteopenia (OPE) or osteoporosis (OPO). The possible influence of some previous diseases and medications on bone density was investigated, too.

Objectives To estimate bone density in patient with Systemic Lupus Erythematosus (SLE) and to investigate the influence of BMI, age at onset of SLE, duration of disease, age in time of study, duration of CS treatment as a possible risk factors for OPE/OPO.

Methods In follow-up study we investigated 57 female patients with SLE, mean age 44.73 ± 11.34 years (min22-max68), mean age at the onset of SLE 35.83 ± 11.18 yr.(15–64). The duration of SLE was 9.03 ± 7.22 yrs (1–32). Corticosteroide therapy was used for 8.40 ± 6.85 yr.(1–32). Body mass density was measured on L2-L4 segment of vertebral spine. DEXA LUNAR osteodensitometer was used. According to T score patients were classified as: normal (N group) 21 patients (T >-1,0), osteopenic (OPE group) 23 pts (-2.5 <T <-1.0), and ospeoporotic (OPO group) 13 pts (T <-2,5).

Results No difference were noted in: BMI and in duration of SLE in groups investigated. The borderline difference was existed between N and OPO group in duration of CS treatment (p = 0.049). The relation between particular data where statistical significance was obtained in groups investigated is presented in the Table 1.

Abstract FRI0145 Table 1

Conclusion Low body mass density was found in elder group of patients with SLE, where the disease started later in perimenopause. Duration of disease, and duration of corticosteroid treatment did not influence BMD. Further studies will consider other factors possibly significant in development of osteoporosis in SLE (subsets of disease, immunological disturbances, cumulative dose of CS and known risk factors for osteoporosis.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.